Hirepa 1mg Tablet contains Repaglinide 1mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Repaglinide belongs to the meglitinide class of drugs and functions by stimulating pancreatic beta cells to release insulin, thereby reducing postprandial blood glucose levels. It is particularly effective in controlling blood sugar spikes following meals and is indicated for patients whose diabetes is not adequately controlled by diet and exercise alone. Hirepa 1mg is typically administered shortly before meals to optimize glycemic control. The drug’s rapid onset and short duration of action allow for flexible dosing tailored to individual meal patterns. Common adverse effects include hypoglycemia, which may manifest as dizziness, sweating, or palpitations, especially if meals are delayed or missed. Other side effects may include gastrointestinal discomfort and mild allergic reactions. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in combination with other antidiabetic agents to avoid hypoglycemia. Regular monitoring of blood glucose levels is essential to ensure efficacy and safety. Hirepa 1mg should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular medical supervision.